ArticleNeuro-oncology advances
Artificial intelligence pipeline predicts the integrated molecular-morphologic risk score of meningiomas from routine preoperative MRI.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in molecular and genetic profiling of meningiomas for improved diagnosis, prognosis, and targeted therapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meningiomas are the most common primary intracranial neoplasms. A significant unmet need exists for noninvasive biomarkers to risk-stratify patients and guide decision-making. The integrated risk score (IRS), which combines histopathological grade, DNA methylation class, and copy number variation (CNV), is a powerful predictor of risk of progression. We aimed to predict the molecular-morphologic IRS from pre-operative T1-weighted contrast-enhanced MRI scans. Methods: We retrospectively analyzed 2 multi-institutional prospectively compiled datasets, including patients with histologically confirmed intracranial meningiomas that had matched DNA methylation and (CNV) profiles. We first developed a radiomics model and trained a support vector machine (SVM) classifier. We then developed a convolutional neural network based on ResNet101, and a vision transformer (ViT). Model performance was assessed using accuracy, area under the curve, precision, recall, and F1-scores. Results: Seventy-six patients met the inclusion criteria. Distributions per WHO class and IRS were 53 (I), 22 (II), 1 (III), and 53 (low), 18 (intermediate) and 5 (high), respectively. The SVM model achieved an AUC of 80.4% and accuracy of 78.2%. The ResNet101 model achieved 85.3% accuracy. The ViT model outperformed, achieving 89.4% accuracy and 89.1% precision in predicting low versus intermediate/high IRS tumors. Conclusions: This study represents the first application of the ViT architecture to predict, with high accuracy, the prognostically highly relevant IRS from routine pre-operative neuroimaging. This pipeline provides a biologically informed and clinically relevant model with potential for future use in early risk stratification and decision support in the management of patients with meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.